stockrow
Friday 6 November 2026
Export RDHL’s income statement to Excel — free account
Redhill Biopharma Ltd.
RDHL Healthcare Drug Manufacturers Specialty & Generic
Redhill Biopharma Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $286,000.00, down 96.4% from fiscal 2024.
0.43
0.00
0.00%
Follow RDHL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 0 | 4 | 8 | 6 | 64 | 86 | 62 | 7 | 8 | 0 | 31 | +12.3% | — | — | — | — | |
| Gross margin, % | 100.00 | 46.94 | 66.06 | 64.09 | 42.68 | 42.39 | 46.06 | 47.03 | 60.31 | 100.00 | 35.16 | 0.0 pt | ||||||
| EBT | (29) | (46) | (39) | (42) | (76) | (98) | (72) | 24 | 0 | (8) | 8 | (13.4%) | ||||||
| EBT margin, % | (29,079.21) | (1,136.61) | (464.35) | (672.45) | (118.36) | (113.98) | (115.97) | 366.25 | 4.48 | (2,825.17) | 25.20 | +26,254.0 pt | ||||||
| Net income | (29) | (46) | (39) | (42) | (76) | (98) | (72) | 24 | (8) | 0 | (47) | (37.5%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 7.83 | 226.38 | 361.90 | 211.82 | 1,768.10 | 1,844.24 | 1,003.25 | 25.20 | 6.53 | 0.09 | 0.00 | (39.1%) | |||||
| Earnings | (2,300.00) | (2,600.00) | (1,700.00) | (1,400.00) | (2,100.00) | (2,100.00) | (1,157.50) | 92.25 | (6.71) | (0.14) | (610.67) | (66.0%) | ||||||
| Cash flow | (2,190.54) | (2,529.32) | (1,491.86) | (1,372.02) | (1,334.59) | (1,398.86) | (473.78) | (138.25) | (7.60) | (3.06) | 0.00 | (51.8%) | ||||||
| Capex | (9.30) | (66.72) | (2.51) | (6.83) | (1,477.31) | (2.47) | (3.21) | (0.04) | (0.01) | 0.00 | 0.00 | (61.8%) | ||||||
| Free cash flow | (2,199.84) | (2,596.05) | (1,494.37) | (1,378.86) | (2,811.90) | (1,401.33) | (477.00) | (138.29) | (7.61) | (3.06) | 0.00 | (51.9%) | ||||||
| Book value | 4,860.54 | 2,546.05 | 2,215.84 | 2,020.27 | 380.88 | 190.86 | (785.71) | 7.99 | (3.80) | 1.35 | 0.00 | (59.7%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 8 | +84.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 1,302.52 | 22.11 | 15.34 | 28.66 | 4.57 | 1.40 | 0.21 | 0.09 | 0.01 | 0.00 | 0.00 | 137.5 | ||||||
| P/B | 2.14 | 2.01 | 2.50 | 3.00 | 21.21 | 13.52 | 0.00 | 0.77 | 7.47 | 0.00 | 0.00 | 5.3 | ||||||
| EV/Sales | 660.25 | 10.86 | 8.97 | 21.65 | 5.40 | 1.95 | 2.89 | 6.16 | 6.35 | 6.50 | 6.43 | 73.1 | ||||||
| EV/FCF | (2.27) | (0.97) | (2.11) | (3.24) | (3.39) | (1.41) | (2.16) | (2.16) | (2.29) | (2.72) | (2.69) | (2.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (28) | (45) | (34) | (41) | (49) | (65) | (29) | (36) | (9) | (10) | (20) | (11.3%) | |||||
| Capex | 0 | (1) | 0 | 0 | (54) | 0 | 0 | 0 | 0 | 0 | 0 | (29.8%) | ||||||
| Free cash flow | (28) | (46) | (35) | (41) | (102) | (65) | (29) | (36) | (9) | (10) | (20) | (11.3%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 62 | 40 | 46 | 43 | (3) | 8 | (112) | (4) | (10) | (13) | (17) | n/m | |||||
| Net debt | (66) | (46) | (53) | (44) | 53 | 47 | 79 | (6) | (5) | (4) | (5) | (26.8%) | ||||||
| Shareholders’ equity | 63 | 45 | 51 | 60 | 14 | 9 | (48) | 2 | (5) | 4 | (1) | (25.8%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (41.65) | (69.24) | (64.83) | (61.98) | (59.90) | (54.09) | (42.15) | 26.29 | (40.24) | (1.98) | 0.00 | +39.7 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | (169.34) | (59.26) | (90.38) | (86.85) | 0.00 | 0.00 | (1,671.30) | 0.00 | (1,671.3) pt | ||||||
| ROE | (47.84) | (84.52) | (80.66) | (76.09) | (206.25) | (859.70) | 362.65 | (103.24) | 632.59 | 206.75 | 0.00 | +254.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 13 | 74 | 75 | 155 | 182 | 201 | 113 | 53 | 35 | 13 | — | 0.0% | |||||
| Revenue/emp, $m | 0.01 | 0.05 | 0.11 | 0.04 | 0.35 | 0.43 | 0.55 | 0.12 | 0.23 | 0.02 | — | +12.3% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Dec 2022 · fundamentals updated 26 Oct 2026
Redhill Biopharma Ltd. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SNOA Sonoma Pharmaceuticals, Inc. | $5.1M | — (loss-making) | — (loss-making) | +59.55% (above 0%: growing) | n/m | +69.31% (above 0%: growing) | 40.23% | (0.62%) | Compare |
| GELS Gelteq Limited | $4.9M | — | — | — | — | −40.15% (below 0%: shrinking) | — | — | Compare |
| YCBD cbdMD, Inc. | $4.4M | — (loss-making) | — (loss-making) | +20.55% (above 0%: growing) | n/m | +34.80% (above 0%: growing) | 54.69% | (20.36%) | Compare |
| APUS Apimeds Pharmaceuticals US, Inc. | $4.1M | — (loss-making) | — | — | n/m | −67.94% (below 0%: shrinking) | — | 0.00% | Compare |
| RDHL Redhill Biopharma Ltd. | $3.8M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | |
| PRFX PainReform Ltd. | $2.3M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BTAIQ BioXcel Therapeutics, Inc. | $2.3M | — (loss-making) | — (loss-making) | +51.67% (above 0%: growing) | n/m | +51.51% (above 0%: growing) | 87.91% | (5,600.55%) | Compare |
| AKAN Akanda Corp. | $2.2M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| SXTC China SXT Pharmaceuticals, Inc. | $2.0M | — (loss-making) | — (loss-making) | −16.76% (below 0%: shrinking) | +92.67% (above 0%: growing) | −107.59% (below 0%: shrinking) | 44.09% | 0.00% | Compare |
| Median of peers | $3.2M | — | — | +36.11% | — | −2.68% | 42.16% | 0.00% |